AMBS News Saturday, July 12, 2014 2:00:43 PM $AMBS
Amarantus BioScience Holdings "AAIC 2014: Understanding the Data Being Presented - LymPro Test(r) Version 2"
ACCESSWIRE - Wed Jul 09, 3:46PM CDT
New York, NY / ACCESSWIRE / July 9, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus' CEO to Host Twitter Chat on Thursday, July 10, 2014 at 4pm EDT
GlobeNewswire - Mon Jul 07, 3:25PM CDT
Amarantus BioScience Holdings, Inc. (OTCBB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will host and participate in a Twitter chat on Thursday, July 10, 2014 from 4-4:30pm EDT via his Twitter handle @G_Commish.
Amarantus Announces Three Data Presentations Related to the Company's LymPro Diagnostic Test at the Alzheimer's Association International Conference (AAIC)
GlobeNewswire - Mon Jul 07, 7:30AM CDT
Amarantus BioScience Holdings, (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that analytical performance, clinical performance and 6-year longitudinal data related to the Company's LymPro Test(R) will be presented at the Alzheimer's Association International Conference (AAIC), held at the Bella Center in Copenhagen, Denmark, July 12-17, 2014.
Amarantus Announces Positive Interim Toxicology Data for MANF in Retinitis Pigmentosa
GlobeNewswire - Wed Jul 02, 8:58AM CDT
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive interim toxicology data for MANF in an ocular safety animal model, relevant to MANF development in Retinitis Pigmentosa. The data produced at a leading ophthalmology contract research laboratory using slit-lamp observations in rabbits demonstrated that an intravitreal injection with MANF was safe and well tolerated in the eye.
Active Trading Briefing For Innovative Advancers with Developing Operations - Company Enters Strategic Partnership With Renown Global Investment Advisory Firm
PR Newswire - Tue Jul 01, 7:45AM CDT
Operations and corporate developments lead to growth trends for advancing companies across various sectors: DirectView Holdings, Inc (OTC: DIRV), Amarantus Bioscience Holdings, Inc. (OTC: AMBS), The ADT Corporation (NYSE: ADT), Tyco International Ltd. (NYSE: TYC) and GoPro Inc. (NASDAQ: GPRO)
Amarantus Independently Confirms Published Chinese Positive MANF Tau Phosphorylation Data for Alzheimer's Disease
GlobeNewswire - Tue Jul 01, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced it has independently confirmed MANF's activity in mitigating tau hyperphosphorylation in pre-clinical models of Alzheimer's disease. The studies commissioned by Amarantus independently confirm data published in 2012 in the Chinese Pharmacological Bulletin entitled "MANF Inhibits Tau Hyperphosphorylation in Cultured Neuronal Cells" in which the authors demonstrated that MANF had a pronounced effect in reducing Tau hyperphosphorylation, reducing cell death, and improving overall cellular health in in vitro models of Alzheimer's disease.
Amarantus BioScience Holdings, Inc. - "MANF Continues to Deliver Heading into 2H-14"
ACCESSWIRE - Mon Jun 30, 2:01PM CDT
New York, NY / June 30, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus and Brewer Sports Announce #C4CT Summit Morning Keynote Presentation by Congressman Chaka Fattah
GlobeNewswire - Wed Jun 25, 5:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports International (BSI), today announced that Congressman Chaka Fattah will be delivering the morning keynote address at the #C4CT Concussion Awareness Summit focused on Traumatic Brain Injury-induced Alzheimer's disease at the United Nations on July 31, 2014. Congressman Fattah will address the Summit regarding policy initiatives currently underway to improve funding for Brain research.
Amarantus Bioscience Holdings, Inc. - "Marching Towards a Revolutionary Therapy for Blindness and Diabetes in Wolfram Syndrome"
ACCESSWIRE - Tue Jun 24, 10:01AM CDT
New York, NY / June 24, 2014 / Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) today published a guest blog post on The Chairman's Blog, written by Dr. Fumihiko Urano, a researcher at the Washington University School of Medicine. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus to Present at the 2014 BIO International Convention
GlobeNewswire - Mon Jun 23, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will be presenting at the 2014 BIO International Convention on Thursday, June 26 at 11:45 AM PDT. The presentation will take place in the Mission Beach Room. Hosted by the Biotechnology Industry Organization (BIO), the conference will take place on June 23-26, 2014 at the San Diego Convention Center in San Diego, California.
Amarantus partners with Washington University School of MedicineJack to evaluate the efficacy of MANF to treat Wolfram disease
M2 - Mon Jun 23, 4:35AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) said on Friday that it plans to evaluate the efficacy of MANF to treat Wolfram-Syndrome-induced blindness in animals in a research partnership with the Washington University School of Medicine in St. Louis.
Amarantus Enters Into Wolfram's Research Collaboration With Washington University School of Medicine
GlobeNewswire - Fri Jun 20, 8:58AM CDT
Amarantus Bioscience Holdings, Inc., (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has entered into a research collaboration with the Washington University School of Medicine in St. Louis to evaluate the efficacy of MANF to treat Wolfram-Syndrome-induced blindness in animals. Dr. Fumihiko Urano, a researcher at the Washington University School of Medicine, will be leading the research. The project initially focuses on evaluating MANF treatment efficacy in retinal cells that are produced from induced pluripotent stem cells, which were derived from Wolfram's patients. Dr. Urano has developed his models of retinal damage with funding from the Jack and JT Snow Foundation.
Amarantus Bioscience Holdings, Inc. - "2H-2014: Milestones Ahead to Position Amarantus for the Up-list"
ACCESSWIRE - Wed Jun 18, 12:15PM CDT
New York, NY / June 18, 2014 / Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus and Brewer Sports Add Partnership With Cavendish Global to #C4CT Alzheimer's Concussion Awareness Summit at United Nations
GlobeNewswire - Wed Jun 11, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports International (BSI), today announced the addition of Cavendish Global as partner at the 3 #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, on Thursday, July 31, 2014 at the United Nations in New York City, NY. The summit will be focused on the emerging hypothesis that brain injury may increase the risk of Alzheimer's disease.
OTC Sector Trading Focus List: GrowBlox Sciences, Inc., Amarantus Bioscience Holdings, Inc., Plandai Biotechnology, Inc., Limitless Venture Group, Inc., Infinex Ventures, Inc.
PR Newswire Europe - Wed Jun 11, 5:30AM CDT
LONDON, June 2, 2014 /PRNewswire/ --
Super Stock Profits Top Five OTC Focus List: Kirin International Holding, Inc. Frozen Food Gift Group, Gray Fox Petroleum Corp, Amarantus Bioscience Holdings, Propanc Health Group Corporation
PR Newswire Europe - Wed Jun 11, 2:25AM CDT
LONDON, May 22, 2014 /PRNewswire/ --
Amarantus to Present at LD Micro Invitational on June 4th
GlobeNewswire - Mon Jun 02, 8:36AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald E. Commissiong, President and CEO will present at the LD Micro Invitational on Wednesday, June 4th, 2014 at the Luxe Sunset Boulevard Hotel in Los Angeles.
Amarantus to Present at the 3rd Annual Marcum MicroCap Conference
GlobeNewswire - Tue May 27, 7:28AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald E. Commissiong, President and CEO will present at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 at the Grand Hyatt Hotel in New York.
Amarantus BioScience Holdings "AAIC 2014: Understanding the Data Being Presented - LymPro Test(r) Version 2"
ACCESSWIRE - Wed Jul 09, 3:46PM CDT
New York, NY / ACCESSWIRE / July 9, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus' CEO to Host Twitter Chat on Thursday, July 10, 2014 at 4pm EDT
GlobeNewswire - Mon Jul 07, 3:25PM CDT
Amarantus BioScience Holdings, Inc. (OTCBB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will host and participate in a Twitter chat on Thursday, July 10, 2014 from 4-4:30pm EDT via his Twitter handle @G_Commish.
Amarantus Announces Three Data Presentations Related to the Company's LymPro Diagnostic Test at the Alzheimer's Association International Conference (AAIC)
GlobeNewswire - Mon Jul 07, 7:30AM CDT
Amarantus BioScience Holdings, (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that analytical performance, clinical performance and 6-year longitudinal data related to the Company's LymPro Test(R) will be presented at the Alzheimer's Association International Conference (AAIC), held at the Bella Center in Copenhagen, Denmark, July 12-17, 2014.
Amarantus Announces Positive Interim Toxicology Data for MANF in Retinitis Pigmentosa
GlobeNewswire - Wed Jul 02, 8:58AM CDT
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive interim toxicology data for MANF in an ocular safety animal model, relevant to MANF development in Retinitis Pigmentosa. The data produced at a leading ophthalmology contract research laboratory using slit-lamp observations in rabbits demonstrated that an intravitreal injection with MANF was safe and well tolerated in the eye.
Active Trading Briefing For Innovative Advancers with Developing Operations - Company Enters Strategic Partnership With Renown Global Investment Advisory Firm
PR Newswire - Tue Jul 01, 7:45AM CDT
Operations and corporate developments lead to growth trends for advancing companies across various sectors: DirectView Holdings, Inc (OTC: DIRV), Amarantus Bioscience Holdings, Inc. (OTC: AMBS), The ADT Corporation (NYSE: ADT), Tyco International Ltd. (NYSE: TYC) and GoPro Inc. (NASDAQ: GPRO)
Amarantus Independently Confirms Published Chinese Positive MANF Tau Phosphorylation Data for Alzheimer's Disease
GlobeNewswire - Tue Jul 01, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced it has independently confirmed MANF's activity in mitigating tau hyperphosphorylation in pre-clinical models of Alzheimer's disease. The studies commissioned by Amarantus independently confirm data published in 2012 in the Chinese Pharmacological Bulletin entitled "MANF Inhibits Tau Hyperphosphorylation in Cultured Neuronal Cells" in which the authors demonstrated that MANF had a pronounced effect in reducing Tau hyperphosphorylation, reducing cell death, and improving overall cellular health in in vitro models of Alzheimer's disease.
Amarantus BioScience Holdings, Inc. - "MANF Continues to Deliver Heading into 2H-14"
ACCESSWIRE - Mon Jun 30, 2:01PM CDT
New York, NY / June 30, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus and Brewer Sports Announce #C4CT Summit Morning Keynote Presentation by Congressman Chaka Fattah
GlobeNewswire - Wed Jun 25, 5:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports International (BSI), today announced that Congressman Chaka Fattah will be delivering the morning keynote address at the #C4CT Concussion Awareness Summit focused on Traumatic Brain Injury-induced Alzheimer's disease at the United Nations on July 31, 2014. Congressman Fattah will address the Summit regarding policy initiatives currently underway to improve funding for Brain research.
Amarantus Bioscience Holdings, Inc. - "Marching Towards a Revolutionary Therapy for Blindness and Diabetes in Wolfram Syndrome"
ACCESSWIRE - Tue Jun 24, 10:01AM CDT
New York, NY / June 24, 2014 / Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) today published a guest blog post on The Chairman's Blog, written by Dr. Fumihiko Urano, a researcher at the Washington University School of Medicine. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus to Present at the 2014 BIO International Convention
GlobeNewswire - Mon Jun 23, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will be presenting at the 2014 BIO International Convention on Thursday, June 26 at 11:45 AM PDT. The presentation will take place in the Mission Beach Room. Hosted by the Biotechnology Industry Organization (BIO), the conference will take place on June 23-26, 2014 at the San Diego Convention Center in San Diego, California.
Amarantus partners with Washington University School of MedicineJack to evaluate the efficacy of MANF to treat Wolfram disease
M2 - Mon Jun 23, 4:35AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) said on Friday that it plans to evaluate the efficacy of MANF to treat Wolfram-Syndrome-induced blindness in animals in a research partnership with the Washington University School of Medicine in St. Louis.
Amarantus Enters Into Wolfram's Research Collaboration With Washington University School of Medicine
GlobeNewswire - Fri Jun 20, 8:58AM CDT
Amarantus Bioscience Holdings, Inc., (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has entered into a research collaboration with the Washington University School of Medicine in St. Louis to evaluate the efficacy of MANF to treat Wolfram-Syndrome-induced blindness in animals. Dr. Fumihiko Urano, a researcher at the Washington University School of Medicine, will be leading the research. The project initially focuses on evaluating MANF treatment efficacy in retinal cells that are produced from induced pluripotent stem cells, which were derived from Wolfram's patients. Dr. Urano has developed his models of retinal damage with funding from the Jack and JT Snow Foundation.
Amarantus Bioscience Holdings, Inc. - "2H-2014: Milestones Ahead to Position Amarantus for the Up-list"
ACCESSWIRE - Wed Jun 18, 12:15PM CDT
New York, NY / June 18, 2014 / Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus and Brewer Sports Add Partnership With Cavendish Global to #C4CT Alzheimer's Concussion Awareness Summit at United Nations
GlobeNewswire - Wed Jun 11, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports International (BSI), today announced the addition of Cavendish Global as partner at the 3 #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, on Thursday, July 31, 2014 at the United Nations in New York City, NY. The summit will be focused on the emerging hypothesis that brain injury may increase the risk of Alzheimer's disease.
OTC Sector Trading Focus List: GrowBlox Sciences, Inc., Amarantus Bioscience Holdings, Inc., Plandai Biotechnology, Inc., Limitless Venture Group, Inc., Infinex Ventures, Inc.
PR Newswire Europe - Wed Jun 11, 5:30AM CDT
LONDON, June 2, 2014 /PRNewswire/ --
Super Stock Profits Top Five OTC Focus List: Kirin International Holding, Inc. Frozen Food Gift Group, Gray Fox Petroleum Corp, Amarantus Bioscience Holdings, Propanc Health Group Corporation
PR Newswire Europe - Wed Jun 11, 2:25AM CDT
LONDON, May 22, 2014 /PRNewswire/ --
Amarantus to Present at LD Micro Invitational on June 4th
GlobeNewswire - Mon Jun 02, 8:36AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald E. Commissiong, President and CEO will present at the LD Micro Invitational on Wednesday, June 4th, 2014 at the Luxe Sunset Boulevard Hotel in Los Angeles.
Amarantus to Present at the 3rd Annual Marcum MicroCap Conference
GlobeNewswire - Tue May 27, 7:28AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald E. Commissiong, President and CEO will present at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 at the Grand Hyatt Hotel in New York.
